SCHEMBL345262

SCHEMBL345262

Nc1nccc(C(F)(F)F)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 2/20 0.45
HSP90AB1 P08238 1/20 0.45
ADRB1 P08588 1/20 0.43
KDM4E B2RXH2 4/20 0.43
HSD17B10 Q99714 2/20 0.43
LOXL2 Q9Y4K0 2/20 0.42
SYK P43405 2/20 0.42
NOS3 P29474 1/20 0.42
NOS2 P35228 1/20 0.42
LOX P28300 1/20 0.41
HRH4 Q9H3N8 1/20 0.41
AURKA O14965 1/20 0.41
PRKACA P17612 1/20 0.41
ADORA2A P29274 1/20 0.41
ALDH1A1 P00352 1/20 0.41
CDC7 O00311 1/20 0.41
CDK2 P24941 1/20 0.41
NUDT1 P36639 2/20 0.40
CA2 P00918 1/20 0.39
CHKA P35790 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30230348 1.00 HSP90AA1 (0.45) HSP90AA1HSP90AB1ADRB1KDM4EHSD17B10
Hydrochloric Acid SCHEMBL31336789 0.98 LOXL2 (0.44) HSP90AA1HSP90AB1ADRB1KDM4EHSD17B10
SCHEMBL29310180 0.78 NUDT1 (0.44) HSP90AA1LOXL2HRH4AURKAPRKACA
SCHEMBL179501 0.77 NUDT1 (0.48) HSP90AA1HSD17B10SYKHRH4AURKA
SCHEMBL17420494 0.77 HSP90AA1 (0.38) HSP90AA1HSP90AB1HSD17B10HRH4AURKA
SCHEMBL3295825 0.74 MALT1 (0.47) ADRB1LOXL2SYKLOX
SCHEMBL27285543 0.74 ADRB1 (0.44) ADRB1LOXL2SYKLOX
SCHEMBL31728177 0.74 NUDT1 (0.46) HSP90AA1HRH4AURKAPRKACAADORA2A
SCHEMBL2036623 0.74 SYK (0.43) SYK
SCHEMBL1968808 0.73 ADRB1 (0.43) ADRB1LOXL2SYKLOX

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 454 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4688155-A1 MORPHOLINE OREXIN RECEPTOR ANTAGONISTS Bial-Portela & CA, S.A. (PT) 2026-02-11 EP claimed
WO-2025125665-A1 FURTHER SUBSTITUTED IMIDAZOLES AS INHIBITORS OF NAV1.8 Grünenthal GmbH (DE) 2025-06-19 WO claimed
CN-120040371-A Compound capable of degrading MYC in targeted manner and application thereof 中国医学科学院医药生物技术研究所 2025-05-27 CN claimed
WO-2025023852-A1 MORPHOLINE OREXIN RECEPTOR ANTAGONISTS BIAL - PORTELA & CA., S.A. (PT) 2025-01-30 WO claimed
WO-2024063670-A1 CYCLIN-DEPENDENT KINASE 7 INHIBITORS Акционерное общество "БИОКАД" 2024-03-28 WO claimed
CN-117165078-A Cyanate resin with low dielectric loss suitable for winding forming process, preparation method and application 中国科学院宁波材料技术与工程研究所 2023-12-05 CN claimed
WO-2023172957-A1 THAIZOLE-PYRIMDIINE CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS PRELUDE THERAPEUTICS, INCORPORATED (US) 2023-09-14 WO claimed
CN-115050893-A Perovskite solar cell based on alkaloid additive 安徽大学 2022-09-13 CN claimed
EP-3559000-A1 BENZIMIDAZOLE DERIVATIVES, PREPARATION METHODS AND USES THEIROF Betta Pharmaceuticals Co., Ltd. (CN) 2019-10-30 EP claimed
EP-3458035-A1 TREATMENT OF SKIN LESIONS PIQUR Therapeutics AG (CH) 2019-03-27 EP claimed
WO-2018113771-A1 BENZIMIDAZOLE DERIVATIVES, PREPARATION METHODS AND USES THEIROF BETTA PHARMACEUTICALS CO., LTD (CN) 2018-06-28 WO claimed
WO-2017198347-A1 TREATMENT OF SKIN LESIONS PIQUR THERAPEUTICS AG (CH) 2017-11-23 WO claimed
EP-2863913-A1 IMIDAZOLYL ANALOGS AS SYK INHIBITORS Merck Sharp & Dohme Corp. (US) 2015-04-29 EP claimed
WO-2013192128-A1 IMIDAZOLYL ANALOGS AS SYK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2013-12-27 WO claimed
EP-1313728-A1 SUBSTITUTED PYRIMIDINES AS SELECTIVE CYCLOOXYGENASE-2 INHIBITORS GLAXO GROUP LIMITED (GB) 2003-05-28 EP claimed
WO-2002018374-A1 SUBSTITUTED PYRIMIDINES AS SELECTIVE CYCLOOXYGENASE-2 INHIBITORS GLAXO GROUP LIMITED (GB) 2002-03-07 WO claimed
EP-0285978-A2 Substituted 1-(2-oxyaminosulfonyl-phenylsulfonyl)-3-(4-trifluoromethyl-pyrimidin-2-yl)-(thio)-ureas BAYER AG (DE) 1988-10-12 EP claimed
EP-4107166-B1 HETEROARYL COMPOUNDS FOR TREATMENT OF COMPLEMENT FACTOR D MEDIATED DISORDERS ACHILLION PHARMACEUTICALS INC (US) 2026-05-27 EP disclosed
EP-0313974-A1 N-substituted derivatives of 1-desoxynojirimycine and 1-desoxymannonojirimycine, process for their preparation and their use as pharmaceuticals BAYER AG (DE) 1989-05-03 EP disclosed
EP-0285978-A2 Substituted 1-(2-oxyaminosulfonyl-phenylsulfonyl)-3-(4-trifluoromethyl-pyrimidin-2-yl)-(thio)-ureas BAYER AG (DE) 1988-10-12 EP disclosed